Vancouver, British Columbia--(Newsfile Corp. - March 14, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces that, further to its news release dated January 24, 2025, 1000141080 Ontario Ltd. ("Mentis AI") has terminated the letter of intent ("LOI") dated January 23, 2025 which set out the terms whereby Entheon would acquire all of the issued and outstanding common shares in the capital of Mentis AI.
About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.
On Behalf of the Board of Directors,
Timothy Ko, CEO, President and Director
For more information, please contact the Company at:
Entheon Biomedical Corp.
Timothy Ko, CEO
1 (604) 562-3932
This email address is being protected from spambots. You need JavaScript enabled to view it.
https://entheonbiomedical.com
| Last Trade: | C$0.10 |
| Daily Volume: | 9,500 |
| Market Cap: | C$1.390M |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
